Medications like semaglutide (a GLP-1 receptor agonist) are gaining attention not only for

Well SupportedSemaglutide reduces the risk of developing Alzheimer's disease by 78% in women and 52% in men over 60 with type 2 diabetes, compared to insulin.

Not SupportedGLP-1 receptor agonists carry potential negative side effects such as lean body mass loss and bone loss.

Partially SupportedGLP-1 receptor agonists may exert neuroprotective effects through mechanisms including reduced neuroinflammation, enhanced neurogenesis and synaptic plasticity, protection against neuronal cell death and excitotoxicity, and improved glymphatic clearance of neurotoxic proteins.

Partially SupportedOptimizing glucose control through diet, exercise, and sleep is foundational for brain health.